Table 6. Oncologic safety of EABS as reported in the literature and in the current study.
| Author | year | Journal | Number | OP method | margin positive | Follow-up(m) | Local recurrence | Distant metastasis | Death | ||
| Tamoki21 | 2001 | Surg Laparosc Endosc Percutan Tech | 6 | E-PM | 0% | one margin+ & convert TM | |||||
| Lee22 | 2006 | World J Surg | 20 | E-PM | 10%(2/20) | Cosmetic f/u 3m | |||||
| Yamashita19 | 2006 | J Nippon Med Sch | 82 | E-PM | 0% | 25 | 0% | 0% | |||
| Yamashita38 | 2008 | Am J Surg | 20 | E-PM | 0% | 12 | 0% | 0% | |||
| Nakajima24 | 2009 | Ann Surg | 551 | E-PM | 20.5%(113/551) | 35 | 4.2%(23/551) | 4.5%(25/551) | 1.3%(7/551) | ||
| Park27 | 2011 | J Breast Cancer | 40 | E-PM | 5%(2/40) | 12 | 0% | ||||
| 681 | BCS | 10.6%(85/681) | 12 | 0.3%(2/681) | |||||||
| Ozaki28 | 2013 | J Laparoendosc Adv Surg Tech | 73 | E-PM | 1.4%(1/73) | 18.1(12–30) | 0% | ||||
| 90 | BCS | 43.7(14–70) | 1.1%(1/90) | ||||||||
| Takahashi29 | 2014 | Surg Today | 100 | E-PM | 4% | 23(9–40) | 0% | 0% | 0% | ||
| 150 | BCS | 3.3% | 0% | 0% | 0% | ||||||
| T-EBSCG | 2016 | Current study | 46 | E-PM | 6.5%(3/46) | 26.8 (3.3–68.6) | 0% | 0% | 0% | ||
| Author | year | Journal | Number | OP method | Reconstruction | Margin positive | Nipple ischemia | Follow-up(m) | Local recurrence | Death | Prothesis loss |
| Nakajima34 | 2002 | Biomed Pharmacother | 17 | E-NSM | LDMF | 0(0%) | 14 | ||||
| Ho32 | 2002 | Surg Endosc | 9 | E-NSM | prothesis, average 235 ml | 0(0%) | |||||
| Ito37 | 2008 | ANZ J Surg | 33 | E-NSM | Prothesis, 30/33 (90.9%) average 235 ml | 8(24.3%) and excised NAC | 3(9.1%) necrosis | 51.2 (16–86) | 0 | 9.1%(3/33) infection with prosthesis removed | |
| Fan30 | 2009 | Chinese Med J | 43 | E-NSM | implant | 0(0%) | 11.6% (5/43) | 16.9±11.2 (6–48) | 0 | 0 | |
| Sakamoto23 | 2009 | Ann Surg Oncol | 87/89 | E-NSM | no mention | 0%, nipple involved 2(2.2%) | 18%(16/89) | 52 (16–80) | 0 | ||
| Tukenmez33 | 2014 | J Laparoendosc Adv Surg Tech | 10/11 | E-NSM | prothesis, implant 4, expander 6 | 0%,subnipple biopsy 1 (9.1%) positive | 0% | 3 | |||
| T-EBSCG | 2016 | Current study | 269 | E-NSME-SSM | Prothesis: implant, expander, TRAM | 3/269 (1.1%) | 12.5% (25/199) | 26.8 (3.3–68.6) | 1.1 (3/269%) | 0.4% (1/269) | Prothesis loss: 2.1%(3/143) |
m: months, TM: total mastectomy, f/u: follow-up, E-PM: endoscopic assisted partial mastectomy, E-NSM: endoscopic assisted nipple sparing mastectomy, E-SSM: endoscopic assisted skin sparing mastectomy, BCS: breast conserving surgery, LDMF: latissimus dorsi myocutaneous flap, TRAM: transverse rectus musculocutaneous flap.